DrugPatentWatch Database Preview
Drugs in Development Information for PSN-632,408
» See Plans and Pricing
What is the development status for investigational drug PSN-632,408?
PSN-632,408 is an investigational drug.
There have been 7 clinical trials for PSN-632,408.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Sanofi, University of Toronto, and University of Alberta.
There are eighty US patents protecting this investigational drug and seven hundred and eighty-one international patents.
Summary for PSN-632,408
| US Patents | 80 |
| International Patents | 781 |
| US Patent Applications | 189 |
| WIPO Patent Applications | 103 |
| Japanese Patent Applications | 54 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 27 |
Recent Clinical Trials for PSN-632,408
| Title | Sponsor | Phase |
|---|---|---|
| Topical Vancomycin Over Sternal Edge in Cardiac Surgery | National Cheng-Kung University Hospital | Phase 4 |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Alberta | N/A |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Toronto | N/A |
Clinical Trial Summary for PSN-632,408
Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408
US Patents for PSN-632,408
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PSN-632,408 | Start Trial | Compositions and methods for diagnosis and treatment of metabolic syndrome | The United States of America, as Represented by the Secretary of the Navy (Washington, DC) | Start Trial |
| PSN-632,408 | Start Trial | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | Start Trial |
| PSN-632,408 | Start Trial | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | Start Trial |
| PSN-632,408 | Start Trial | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | Start Trial |
| PSN-632,408 | Start Trial | Compositions and methods for diagnosis and treatment of inflammation | The United States of America as represented by the Secretary of the Navy (Washington, DC) | Start Trial |
| PSN-632,408 | Start Trial | Biguanide compositions and methods of treating metabolic disorders | Anji Pharma (US) LLC (Boxford, MA) | Start Trial |
| PSN-632,408 | Start Trial | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | Sanofi-Aventis (Paris, FR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PSN-632,408
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PSN-632,408 | Argentina | AR103371 | 2035-01-07 | Start Trial |
| PSN-632,408 | European Patent Office | EP3247346 | 2035-01-07 | Start Trial |
| PSN-632,408 | Japan | JP2018505158 | 2035-01-07 | Start Trial |
| PSN-632,408 | Japan | JP2020055875 | 2035-01-07 | Start Trial |
| PSN-632,408 | Taiwan | TW201639557 | 2035-01-07 | Start Trial |
| PSN-632,408 | World Intellectual Property Organization (WIPO) | WO2016111843 | 2035-01-07 | Start Trial |
| PSN-632,408 | Argentina | AR091089 | 2031-01-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
